The Journal of Clinical Investigation (Jan 2023)

Superenhancer activation of KLHDC8A drives glioma ciliation and hedgehog signaling

  • Derrick Lee,
  • Ryan C. Gimple,
  • Xujia Wu,
  • Briana C. Prager,
  • Zhixin Qiu,
  • Qiulian Wu,
  • Vikas Daggubati,
  • Aruljothi Mariappan,
  • Jay Gopalakrishnan,
  • Matthew R. Sarkisian,
  • David R. Raleigh,
  • Jeremy N. Rich

Journal volume & issue
Vol. 133, no. 2

Abstract

Read online

Glioblastoma ranks among the most aggressive and lethal of all human cancers. Self-renewing, highly tumorigenic glioblastoma stem cells (GSCs) contribute to therapeutic resistance and maintain cellular heterogeneity. Here, we interrogated superenhancer landscapes of primary glioblastoma specimens and patient-derived GSCs, revealing a kelch domain–containing gene, specifically Kelch domain containing 8A (KLHDC8A) with a previously unknown function as an epigenetically driven oncogene. Targeting KLHDC8A decreased GSC proliferation and self-renewal, induced apoptosis, and impaired in vivo tumor growth. Transcription factor control circuitry analyses revealed that the master transcriptional regulator SOX2 stimulated KLHDC8A expression. Mechanistically, KLHDC8A bound chaperonin-containing TCP1 (CCT) to promote the assembly of primary cilia to activate hedgehog signaling. KLHDC8A expression correlated with Aurora B/C Kinase inhibitor activity, which induced primary cilia and hedgehog signaling. Combinatorial targeting of Aurora B/C kinase and hedgehog displayed augmented benefit against GSC proliferation. Collectively, superenhancer-based discovery revealed KLHDC8A as what we believe to be a novel molecular target of cancer stem cells that promotes ciliogenesis to activate the hedgehog pathway, offering insights into therapeutic vulnerabilities for glioblastoma treatment.

Keywords